Desmoplastic tumors | Samples | CAF subpopulations | Markers | Functions | References |
---|---|---|---|---|---|
Breast cancer | Patient samples | myCAF | FAP, ACTA2 and PDPN | ECM-producing | [38] |
iCAF | CXCL12 | Immune evasion | |||
Breast cancer and ovarian cancer | Patient samples | CAF-S1 | FAP, αSMA | Immunosuppressive Tumor invasion Lymph-nodes metastasis | |
CAF-S2 | Not reported | Not reported | |||
CAF-S3 | PDGFRβ, FSP1 and CD29 | Not reported | |||
CAF-S4 | αSMA, CD29 | Lymph-nodes metastasis Tumor invasion | |||
Breast cancer | Patient samples | CD146posCAFs | CD146pos | Sustains estrogen-dependent proliferation | [43] |
CD146negCAFs | CD146neg | Enhance tamoxifen resistance | |||
Breast cancer and lung cancer | Patient samples | CD10+GPR77+CAF | CD10 and GPR77 | Promote tumor formation Sustain CSCs | [45] |
Lung cancer | Patient samples | 5 clusters | αSMA (cluster 2) | Angiogenesis | [46] |
Pancreatic ductal adenocarcinoma | Patient samples; KPC mice tumors | myCAF | αSMA, transgelin, TPM1, TPM2, MMP11, POSTN and homeobox transcription factor | ECM-producing | |
iCAF | IL-6, IL-8, IL-11, Lif, CXCL12, PDGFRα, HAS1 and HAS2 | Immunosuppressive/tumor promoting | |||
Antigen-presenting CAF | MHC II, CD74 and serum amyloid A3 | Antigen-present Immunomodulatory | |||
Pancreatic ductal adenocarcinoma | Patient samples | CAF-A | POSTN | Tumor proliferation Tumor invasion | [40] |
CAF-B | Myosin-11 | Lymph-node metastasis | |||
CAF-C | PDPN | Promote immune | |||
CAF-D | Not reported | Not reported | |||
Colorectal cancer | Patient samples | CAF-A | COL1A2, MMP2 and DCN | ECM-producing | [49] |
CAF-B | PDGFA, TAGLN and ACTA2 | Not reported | |||
Cholangiocarcinoma | Patient samples; KRAS/p19 and YaP/AKT mouse tumors | myCAF | COL1A1, HAS2/HA | ECM-producing | [39] |
iCAF | HGF | Tumor promoting | |||
PF/mesCAF | PF/mesothelial | Not reported |